Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)

NCT03035032 is registered in ClinicalTrials.gov with Astellas Pharma Singapore Pte. Ltd. as lead sponsor.

NCT NCT03035032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03035032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
Lead sponsor
Astellas Pharma Singapore Pte. Ltd.
Phase
Phase 4
Overall status
Completed
Start date
June 23, 2017
Completion date
November 19, 2019
Enrollment
107 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer